APOE {epsilon}4 and bapineuzumab: Infusing pharmacogenomics into Alzheimer disease therapeutics

Neurology. 2009 Dec 15;73(24):2052-3. doi: 10.1212/WNL.0b013e3181c6784a. Epub 2009 Nov 18.
No abstract available

Publication types

  • Editorial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Alzheimer Disease / drug therapy*
  • Alzheimer Disease / genetics*
  • Alzheimer Disease / psychology
  • Amyloid beta-Peptides / immunology
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / immunology
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Apolipoprotein E4 / genetics*
  • Cognition / drug effects
  • Heterozygote
  • Humans
  • Injections, Intravenous
  • Treatment Outcome

Substances

  • Amyloid beta-Peptides
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Apolipoprotein E4
  • bapineuzumab